Business of Medicine
Commentary
Cancer Treatment 101: A Primer for Non-Oncologists
Doctor explains why he thinks time of diagnosis is the best time for molecular testing of a new malignant tumor.
Latest News
Physicians Lament Over Reliance on Relative Value Units: Survey
“The current RVU system encourages unnecessary procedures, hurting patients.”
Latest News
Will Compounding ‘Best Practices’ Guide Reassure Clinicians?
“This structured approach reduces the risk of variability and ensures that compounded drugs meet high-quality standards, thus enhancing their...
Feature
Jeffrey Weber, MD, PhD, Giant of Cancer Care, Dies
He was a principal investigator on many studies, including pivotal clinical drug trials in melanoma.
Latest News
Who’s Behind Cosmetic Procedures at MedSpas?
Researchers enlisted help from "secret shoppers" who contacted MedSpas to ask about the level of training, if patients underwent a review of...
Feature
Doctors Are Seeking Professional Coaches More Often. Here’s Why
More and more doctors are using professional coaching to manage life in medicine. The coaches, also physicians, say it might be a cure for burnout...
Feature
FTC Interim Report on Pharmacy Middlemen Is First Step of Many Needed in Addressing Drug Costs, Access
Madelaine Feldman, MD, has been a vocal PBM critic for years. She sees a recent FTC interim report as evidence of the need for congressional...
Commentary
What Would ‘Project 2025’ Mean for Health and Healthcare?
Conservative group–backed plan intends to alter the processes and/or funding of CDC, NIH, Medicaid, and other agencies.
Latest News
Recommendations From a Pediatric Dermatologist on Using AI in Daily Practice
Many academic institutions are creating “walled gardens” — private areas of AI access that don’t allow patient information to “leak out.”
News from the FDA/CDC
FDA Approves Lymphir for R/R Cutaneous T-Cell Lymphoma
The immunotherapy is a reformulation of denileukin diftitox that was initially approved for certain patients with persistent or recurrent...
Feature
Immunotherapy May Be Overused in Dying Patients With Cancer
“There are patients who are getting immunotherapy who shouldn’t,” according to a surgical oncologist from Yale.